Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Adagene in a research note issued to investors on Monday, January 27th. HC Wainwright analyst A. He anticipates that the ...

IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47–SIRPα interaction in order to promote the phagocytosis of cancer cells by macrophages. It binds to human CD47 with ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Chinese biopharma CStone Pharmaceuticals today announced a strategic commercialization partnership with SteinCares, which will gain the commercialization rights for sugemalimab in 10 Latin America ...

Massachusetts-based company is developing a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, called obexelimab, which is in a phase 3 trial as a treatment for IgG4-related disease ...

Tevimbra, a humanized IgG4 anti-PD-1 monoclonal antibody, was recently approved by the European Commission for the treatment of patients with advanced or metastatic esophageal squamous cell ...